论文部分内容阅读
目的:探讨雷贝拉唑联合莫沙必利和熊去氧胆酸对72例胆汁返流性食管炎的临床疗效。方法:96例经食管镜检查证实的胆汁返流性食管炎患者随机分为3组,每组32例。A组服用雷贝拉唑(10mg,每日1次),熊去氧胆酸(250mg,每日1次,睡前服用);B组服用雷贝拉唑(10mg,每日1次),莫沙必利(5mg,每日3次,饭前30min服用);C组同时服用雷贝拉唑、莫沙必利和熊去氧胆酸。观察治疗后烧心、返酸、胸骨后疼痛等症状变化情况。结果:治疗后3组患者临床症状均明显减轻,有效率分别为84.37%、81.25%和96.87%。C组与前两组比较差异有统计学意义(P<0.05)。食管内胆汁返流消失率分别为75.00%、71.87%、和90.62%,C组与前两组比较差异有统计学意义(P<0.05)。结论:雷贝拉唑联合莫沙必利和熊去氧胆酸可减少食管内胆汁返流,能有效缓解胆汁返流性食管炎的症状。
Objective: To investigate the clinical efficacy of rabeprazole combined with mosapride and ursodeoxycholic acid on 72 cases of bile reflux esophagitis. Methods: Ninety-six patients with biliary reflux esophagitis confirmed by esophagoscopy were randomly divided into three groups (n = 32 in each group). Group A took rabeprazole (10 mg once daily), ursodeoxycholic acid (250 mg once daily, taken at bedtime); group B took rabeprazole (10 mg once daily) Mosapride (5mg, 3 times a day, taking 30min before meals); C group taking rabeprazole, mosapride and ursodeoxycholic acid at the same time. Observed after treatment, heartburn, acid reflux, sternum pain and other symptoms changes. Results: After treatment, the clinical symptoms of the three groups were significantly reduced, the effective rates were 84.37%, 81.25% and 96.87% respectively. There was significant difference between group C and the former two groups (P <0.05). The disappearance rates of reflux in the esophagus were 75.00%, 71.87%, and 90.62%, respectively. The difference between the two groups was statistically significant (P <0.05). Conclusion: Rabeprazole combined with mosapride and ursodeoxycholic acid can reduce the esophageal bile reflux, can effectively alleviate the symptoms of bile reflux esophagitis.